ANI PHARMACEUTICALS INC

(c) Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).

On June 16, 2025, Christopher Mutz, Senior Vice President, Head of Rare Disease of the Company, adopted a Rule 10b5-1 trading plan. Mr. Mutz’s Rule 10b5-1 trading plan provides for a term commencing on January 7, 2026 and ending on March 20, 2026 and for the sale of up to(i)4,019 shares of the common stock of the Company, (ii) up to 21,717 shares of common stock upon the vesting of certain RSAs, subject to reduction for shares withheld by the Company to satisfy tax withholding obligations and (iii) up to 5,789 shares of common stock upon the vesting of certain PSUs, subject to the satisfaction of certain performance conditions and reduction for shares withheld by the Company to satisfy tax withholding obligations.